7,754 press releases indexed under healthcare.
First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needs FRANKLIN LAKES, N.J., Sept. 14, 2026...
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the...
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18 F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).
First-in-human study in British Journal of Urology International confirms bladder cancer treatment can shift from the operating room to the outpatient clinic-enabling complete treatment and diagnostic sampling in minutes on awake patients. GOTHENBURG, Sweden, Sept. 14, 2026 /PRNewswire/...
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
CHICAGO, September 14, 2026--Artisight, the leader in Smart Hospital technology, acquired TMG Global, a technology services firm with deep expertise in healthcare infrastructure, site readiness, and large-scale technology deployments. The acquisition strengthens Artisight’s ability to integrate smart hospital technology across complex clinical environments in leading U.S. hospitals.
NEW YORK, September 14, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 56,650 common shares of the Company (the "Options") with effective grant dates of September 1
Research Highlights: Increasing pulse pressure (the gap between the upper and lower numbers in blood pressure readings), long attributed to falling estrogen levels caused by menopause, begins about two decades before women enter menopause, according to an analysis from the large and multi-generation Framingham Heart Study. The study suggests that healthcare professionals should pay greater attention to women with a wide (higher number) pulse pressure because it is a sign that the body’s largest blood vessel (the aorta) is becoming stiffer and less flexible, therefore, increasing the risk of heart disease. Wide pulse pressure is a major risk factor for cardiovascular disease, dementia and kidney disease and may make high blood pressure less responsive to some medication treatments. DALLAS -
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial ( NCT05671510 ) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.
Novo Nordisk will mark the beginning of its next chapter by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name ...
An upcoming educational feature explores the critical intersection of community-driven workforce programs and modern rural hospital sustainability. LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- The educational series "All Access hosted by Andy Garcia" will document a compelling solution to...
CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug...